When Algorithmic Systems Interpret Your Asset, Alignment Matters.
Clinical stage therapeutic programs are increasingly interpreted by AI generated summaries and automated knowledge surfaces. Small inconsistencies across public materials can become amplified.
We help ensure that what is publicly available about your asset is represented accurately, consistently, and in context.
NDA friendly. Clear next steps.
Why This Matters
In founder led and investor backed biopharma, enterprise value is often concentrated in a small number of development programs.
Automated systems synthesize information from:
- •Clinical trial registries
- •Press releases
- •Scientific publications
- •Conference abstracts
- •Third party media coverage
- •Historical filings
If terminology, phase descriptions, endpoints, indications, or positioning differ across sources, algorithmic summaries may reflect those inconsistencies.
This can introduce friction in:
- •Investor diligence
- •Business development conversations
- •Partner evaluations
- •Executive hiring discussions
We focus on interpretive alignment, not promotion.
What We Actually Do
We collaborate with:
- •Scientific leadership
- •Clinical development
- •Business development
- •Ownership and founders
To identify where public facing materials may produce unintended interpretive drift.
Then we:
- •Map how answer systems summarize the asset
- •Identify inconsistency patterns
- •Align terminology and structure across sources
- •Strengthen clarity without altering scientific accuracy
This is about representation discipline.
Not narrative spin.
Designed for Confidential Environments
We operate comfortably within:
- •NDA frameworks
- •Pre approval environments
- •Private capital structures
- •Board level discussions
We don't speculate. We don't embellish. We don't introduce forward looking claims.
We focus strictly on interpretive precision.
Request a Clinical Narrative Review
Identify where inconsistent public materials may create interpretive drift in AI-generated summaries of your asset.